Mind Medicine Australia is seeking to establish safe and effective psychedelic-assisted treatments for mental illness in Australia. As a registered charity (DGR-1 status), we are supporting clinical research and working towards regulatory-approved and evidence-based psychedelic-assisted therapies. We operate as a nexus between medical practitioners, academia, government, regulatory bodies, philanthropists, and other partners.
Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses. We do not advocate for non-clinical use of psychedelics, MDMA, or any other prohibited substances, nor do we advocate for any changes to the law with respect to non-clinical use. Our focus is wholly clinical.
THE CURRENT STATE OF MENTAL illness
About 15% of the world’s population (1.1 billion people) currently have a mental illness. In Australia, mental illness is the leading cause of non-fatal disease burden, and the third leading cause of total disease burden, and nearly half of all Australians will experience a mental illness at some point in their lives. If you are not affected, someone dear to you is likely to be. In addition, the annual cost of mental illness in Australia is about $60 billion. Research and treatment expenses continue to rise, yet rates of mental illness indicate that we’re losing the battle. New approaches are urgently needed to address this immense suffering and cost to society.
a new paradigm
Psychedelic-assisted psychotherapy is currently being tested in many countries, and has demonstrated remarkable promise in treating various mental illnesses, including depression, anxiety, addiction, and trauma. The treatment combines a short program of psychotherapy with just a few medicinal doses of psilocybin or MDMA. In the 1950s and 60s, psychedelic treatments had a major impact in psychiatry, and many considered it the next big thing in mental health treatment. But for largely political reasons, psychedelic research and therapy were effectively blocked from around 1970. Over the past decade, that research has finally begun again. In rigorous and well-controlled trials with proper clinical support, psychedelic treatments are safe, and frequently lead to remission after only a short program, and even where current treatments have failed. The results have been so compelling that the US Food and Drug Administration (FDA) have designated psilocybin- and MDMA-assisted psychotherapies as ‘breakthrough therapies’, expediting their research and development.
A CALL TO ACTION
Over one hundred psychedelic trials are currently active or have been recently completed, and Australia’s first clinical trial – sponsored by PRISM at St Vincent’s Hospital, and part-funded by Mind Medicine Australia – is launching in 2019. We are seeing the emergence of a new paradigm in mental health treatment, with mounting evidence indicating impressive outcomes. If the results from current large ‘Phase 3’ trials are positive, psychedelic medicines may be available within the next 3 to 5 years. This is an historic moment in mental health research and treatment. Here at Mind Medicine Australia we know there is no easy solution for mental illness. But we owe it to those suffering to not be held hostage by historical prejudices, and to explore the best solutions available.
Launch Event of Mind Medicine Australia
We celebrated the launch of Mind Medicine Australia on 13th February 2019 with a community of Australian changemakers at The University of Melbourne.
Please watch and share videos from the launch of Mind Medicine Australia.
Professor David Nutt’s International Keynote lecture titled ‘Psychedelic therapy: Changing the paradigm for mental health’
Launch Address by Peter Hunt AM and Tania de Jong AM